Results 221 to 228 of about 14,735 (228)

CYP2C8 polymorphisms among malaria patients in Guinea-Bissau

2008
Cytochrome P450 (CYP) 2C8 is the major enzyme responsible for the metabolism of many clinically important drugs including the antimalarial amodiaquine (AQ). This study investigated in 91 malaria-infected patients from Guinea-Bissau, the prevalence of CYP2C8 variants CYP2C8*2, CYP2C8*3 and CYP2C8*4, which may have important clinical implications for the
openaire   +1 more source

The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide

British Journal of Clinical Pharmacology, 2006
Kim Brosen, Per Damkier
exaly  

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy

Breast Cancer Research and Treatment, 2014
Daniel L Hertz, John Jack, Alison A Motsinger-Reif   +2 more
exaly  

The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects

British Journal of Clinical Pharmacology, 2006
Per Damkier, Kim Brosen
exaly  

Selexipag contraindicated with strong CYP2C8 inhibitors

Reactions Weekly, 2017
openaire   +1 more source

CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients

British Journal of Cancer, 2009
exaly  

Genetic polymorphism of CYP2C8 in three Malaysian ethnics: CYP2C8*2 and CYP2C8*3 are found in Malaysian Indians

Journal of Clinical Pharmacy and Therapeutics, 2005
exaly  

Amodiaquine Metabolism is Impaired by Common Polymorphisms in CYP2C8: Implications for Malaria Treatment in Africa

Clinical Pharmacology and Therapeutics, 2007
exaly